Alcohol is a well-established risk factor for hepatocellular carcinoma (HCC), but the mechanisms by which it promotes liver cancer are not well understood. Several studies have shown that cellular protein arginine methylation is inhibited by alcohol. Arginine methylation is controlled by the reciprocal activity of protein arginine methyltransferases, primarily protein arginine methyl transferase 1 (PRMT1), and a demethylase Jumonji C domain-containing protein 6 (JMJD6). The aim of this study was to explore the role of arginine methylation changes in alcohol pathogenesis. We found that PRMT1 activity is inhibited in livers of mice fed with alcohol compared to pair-fed mice. Using hepatocyte-specific PRMT1 knockout mice, we identified that loss of PRMT1 results in enhanced hepatocyte proliferation and a 33% increase in liver size. This increased hepatocyte proliferation was associated with reduced expression of hepatocyte nuclear factor 4 alpha (Hnf4a), an important regulator of liver tumorigenesis. We found that PRMT1 regulates Hnf4a expression directly through arginine methylation at the (Hnf4a) promoter. In the absence of PRMT1, JMJD6 can demethylate the Hnf4a promoter and suppress its expression. We were able to restore Hnf4a expression and abolish the increase in hepatocyte proliferation by knockdown of JMJD6 in PRMT1 knockout mice. Knockdown of JMJD6 in alcohol-fed mice similarly increased Hnf4a expression. We then examined whether loss of arginine methylation might play a role in alcohol-associated liver cancers. We examined 25 human HCC specimens and found a strong correlation (R 5 0.8; P < 0.01) between arginine methylation levels and Hnf4a expression in these specimens, suggesting that the above mechanism is relevant in patients. Conclusion: Taken together, these data suggest that PRMT1 inhibition, such as induced by alcohol, may result in epigenetic changes leading to loss of Hnf4a. This effect may contribute to alcohol's ability to promote liver tumors. (HEPATOLOGY 2018;67:1109-1126. P rotein arginine methylation is a common posttranslational modification that plays a role in multiple pathways, including cell-cycle control, RNA processing, and DNA replication. The protein arginine methyltransferase, protein arginine methyl transferase 1 (PRMT1), is responsible for around 85% of total cellular arginine methylation (1) and catalyzes arginine monomethylation and dimethylation using Sadenosylmethionine (SAM) as a methyl donor. PRMT1 methylates histone H4 at arginine 3,
generating H4R3me2a, a transcriptional activation mark, (1) (2) (3) (4) (5) thus contributing to the histone code. As a transcriptional coactivator, PRMT1 is recruited to promoters by a number of different transcription factors. (3, 6, 7) Abnormal function of PRMT1 is closely associated with several types of cancer and cardiovascular disease. Arginine methylation impacts gene transcription and splicing as well as upstream signal transduction. (4) Until recently, arginine methylation was thought to be an irreversible modification attributed to the absence of demethylation enzymes. But PRMT1 is involved in processes such as cell-cycle control, where responses are of short duration and signal turnover is rapid. This suggests a possible dynamic regulation of this modification. Protein arginine demethylases have not been well described, but one of the Jumonji family proteins, Jumonji C domain-containing protein 6 (JMJD6), has been reported to have arginine demethylase activity. (8, 9) JMJD6 is a dioxygenase that can act as both an arginine demethylase and a lysyl-hydroxylase. It is required during embryogenesis and is a key regulator of hematopoietic differentiation through its targets, U2 auxiliary factor (U2AF) 2/U2AF65. (10) We and others have recently shown that JMJD6 can demethylate PRMT1 targets. (8, 9, 11) Around 40% of individuals who chronically consume alcohol develop fatty liver, which can advance to alcoholic hepatitis, cirrhosis, and cancer. Alcohol interacts with other causes of liver disease, including hepatitis B and C, and conditions, such as diabetes and obesity, to increase the risk for developing hepatocellular carcinoma (HCC), either synergistically or additively. (12) (13) (14) A number of studies have been performed to define the changes induced by alcohol consumption that can lead to progression of liver disease and cancer development. Mouse models suggest that chronic EtOH consumption stimulates hepatocyte proliferation through activation of the Wnt/b-catenin signaling pathway, thus promoting tumorigenesis following an initiating insult in the liver. (15, 16) Others suggest that increased neutrophil and macrophage activation induced by chronic alcohol exposure contributes to hepatocyte damage and tumor development. (16) (17) (18) We have recently shown that PRMT1 activity and cellular arginine methylation are inhibited in models of liver disease induced by alcohol and hepatitis C virus (HCV) infection. (19) This study examines the role of PRMT1 in alcohol pathogenesis in the liver, exploring one possible mechanism by which alcohol promotes tumor development in the liver. We found that alcohol inhibits arginine methylation in the liver. Arginine methylation levels in hepatocytes are regulated by PRMT1 and JMJD6 levels, which, in turn, control hepatocyte nuclear factor 4 alpha (HNF4a) activity and expression. Alcohol-induced PRMT1 inhibition results in reduced HNF4a expression, which can contribute to alcohol pathogenesis and cancer progression.
Materials and Methods

MICE
C57BL/6NTac-Prmt1 tm1a(EUCOMM)Wtsi /WtsiCnbc mice were obtained from EUCOMM (EUCOMM project: 40181) and bred with Flp recombinase mice to get homozygous Prmt1 floxed breeders as decribed. (20) These mice were next crossed with Albumin-Cre mice to generate mice lacking Prmt1 in hepatocytes. For experiments, PRMT1 fl/fl Cre/wt mice were used, together with PRMT fl/fl wt/wt littermates, as a control. All mice were housed in a temperature-controlled, specific, pathogen-free environment with 12-hour light-dark cycles and fed regular mouse chow and water ad libitum. All animal handling procedures were approved by the Institutional Animal Care and Use Committees at the University of Kansas Medical Center (Kansas City, KS).
ANTIBODIES USED Primary Antibodies
Anti-PRMT1 (F339), Acetyl-Histone H3 (Lys27) (D5E4), anti-CyclinD, and anti-b-catenin antibodies were from Cell Signaling, Danvers, MA. Anti-Lamin B (C20) and anti-b-actin were from Santa Cruz, Dallas, TX. Rabbit Anti-PRMT1 antibody (against amino acids [aa] 300-361), were from Abcam, Cambridge, UK. Antiasymmetric-dimethyl-arginine antibodies and AntiH4R3me2a antibodies were from ActiveMotif, Carlsbad, CA. Monoclonal anti-HNF4a (H1415) antibodies were from R&D Systems Inc, Minneapolis, MN. Mouse anti-b-actin, mouse Monoclonal Anti-PRMT1 clone 171 (against aa 1-361) and Anti-JMJD6 (SAB3500233) antibodies were from Sigma-Aldrich (St. Louis, MO). Anti-GAPDH (glyceraldehyde 3-phosphate dehydrogenase) was from Ambion, Austin, TX.
Secondary Antibodies
IRDye 800CW goat anti-mouse immunoglobulin G (IgG) and IRDye 680RD goat anti-rabbit IgG were from Li-COR, Lincoln, NE. General horseradish peroxidase-conjugated secondary antibodies were from Southern Biotechnology Associates (Birmingham, AL).
CELL CULTURE
Huh7.5 cells (21) (obtained from Dr. Charles Rice) were maintained in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum, 50 U mL -1 of penicillin, and 50 mg mL -1 of streptomycin. AMI-1 was obtained from EMD4 Biosciences (Burlington, MA) and used at 10 lM for 16-24 hours preceding harvest. Cells were transfected using Lipofectamine LTX transfection reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's protocol.
VECTORS
p6352 MSCV-CMV-CMV-Flag-HA-JMJD6 was provided by Peter Howley through Addgene (Addgene plasmid 31358). pCMV6-PRMT1 was from Origene, Rockville, MD. AAV8.TBG.PI.Null.bGH (AV-8-PV0148) and AAV8.TBG.PI.Cre.rBG (AV-8-PV1091) were a gift from Dr. Lisa Zhang and were from Penn Vector Core (Philadelphia, PA). AAV8-GFP-U6-m-JMJD6-shRNA (shAAV-262522) and AAV8-GFP-U6-scrmb-shRNA were from Vector BioLabs (Malvern, PA).
HUMAN SPECIMENS
De-identified human liver specimens from liver explants were obtained from the Liver Center Tissue Bank at the University of Kansas Medical Center. All studies using human tissue samples were approved by the Human Subjects Committee of the University of Kansas Medical Center.
REAL-TIME PCR
RNA was extracted from cultured cells using the RNeasy Mini Kit (Qiagen, Venlo, Netherlands). Complementary DNA was generated using the RNA reversetranscription kit (catalogue no.: 4368814; Applied Biosystems, Foster City, CA). Quantitative real-time RT-PCR was performed in a CFX96 Real time system (BioRad) using specific sense and antisense primers combined with iQ SYBR Green Supermix (Bio-Rad, Hercules, CA) for 40 amplification cycles: 5 seconds at 958C, 10 seconds at 578C, and 30 seconds at 728C.
CHROMATIN IMMUNOPRECIPITATION ASSAY
Chromatin immunoprecipitation (ChIP) was performed as described. (20) 
WESTERN BLOTTINGS
Protein extracts (15 lg) were subjected to 10% SDS/polyacrylamide gel electrophoresis, electrophoretically transferred to nitrocellulose membranes (Amersham Hybond ECL, GE Healthcare, Greenwood, MO), and blocked in 3% bovine serum albumin/phosphate-buffered saline (PBS) at room temperature (RT) for 1 hour. Primary antibodies were incubated overnight at manufacturer-recommended concentrations. Immunoblottings were detected with the ECL Plus Western Blotting Detection System (Amersham Biosciences, Piscataway, NJ) or using near-infrared fluorescence with the ODYSSEY Fc, Dual-Mode Imaging system (Li-COR). Expression levels were evaluated by quantification of relative density of each band normalized to that of the corresponding b-actin or GAPDH band density.
IMMUNOHISTOCHEMISTRY
Immunostaining on formalin-fixed sections was performed by deparaffinization and rehydration, followed by antigen retrieval by heating in a pressure cooker (1218C) for 5 minutes in 10 mM of sodium citrate (pH 6.0). Peroxidase activity was blocked by incubation in 3% hydrogen peroxide for 10 minutes. Sections were rinsed three times in PBS/PBS-T (0.1% 
STATISTICAL ANALYSIS
Results are expressed as mean 6 SD. The Student t test, paired t test, Pearson's correlation, or one-way analysis of variance with Bonferroni's post-hoc test was used for statistical analyses. A P value <0.05 was considered significant.
Results
HEPATOCYTE-SPECIFIC PRMT1 DELETION RESULTS IN AN INCREASE OF HEPATOCYTE PROLIFERATION
Our previous work has shown that PRMT1 activity, but not protein level, is reduced by alcohol exposure in Huh 7.5 cells. (19) We confirmed the inhibition using an in vivo model of Lieber-DeCarli alcohol feeding for 3 weeks in wild-type (WT) mice. Because PRMT1 protein expression is not affected by alcohol, we measured PRMT1 activity by immunohistochemical staining for PRMT1-dependent asymmetric dimethyl arginine (ADMA). (4) The anti-ADMA antibody broadly recognizes dimethylated proteins of various molecular sizes (Supporting Fig. S1A ). We found that alcohol feeding dramatically reduced ADMA levels in alcohol-fed mice compared to mice fed control liquid diet (Fig. 1A) . Additionally we confirmed the reduction of PRMT1 activity by analyzing methylation of a well-described target protein, Src-associated in mitosis of 68kD (Supporting Fig. S1B ).
To study how loss of PRMT1 activity can contribute to alcohol pathogenesis, we created hepatocytespecific PRMT1 knockout (KO) mice by breeding PRMT1 fl/fl mice with albumin-Cre mice. Similar KO mice have been described before to have a defect in PRMT1-dependent forkhead box protein O1 (FOXO1) activity. (22) We confirmed that KO mice show a loss of ADMA staining in hepatocytes compared to their WT littermates (Fig. 1B) . The decrease in ADMA was similar to that observed in alcohol-fed mice (compare Fig. 1A and 1B) . Next, we analyzed livers by hematoxylin-eosin (H&E) staining and found that PRMT1 KO mice developed "nuclear atypia," but otherwise appeared normal (Fig. 1C) . Nuclear atypia is characteristic of preneoplastic changes and malignancy and often a sign of dedifferentiation and higher proliferation. (23) (24) (25) This phenotype correlated with increased levels of hepatocyte proliferation in the KO mice ( Fig. 1C ) and an increase in liver size (Fig. 1D ). The phenotype was not sex specific; we observed similar liver weight changes in both male and female mice (Fig. 1D ). Interestingly we found that PRMT1 KO mice had high levels of serum alanine aminotransferase (ALT) without apparent liver injury; we found that this was attributed to increased expression of the ALT gene, glutamic-pyruvic transaminase (gpt), in livers of those mice (Supporting Fig. S2A,B) .
PRMT1 DELETION RESULTS IN AN INCREASE IN b-CATENIN EXPRESSION AND INHIBITION OF HNF4a EXPRESSION
To study the mechanism of PRMT1-dependent regulation of hepatocyte proliferation, we performed PCR array analysis of proliferation-related gene expression in whole-liver mRNA from WT and PRMT1 KO mice (Supporting Fig. S3 ). Examples of genes that are differentially regulated in PRMT1 KO livers are presented in Fig. 2A . The genes that were up-regulated or down-regulated more than 1.8-fold were used for Ingenuity Pathway Analysis (IPA). We found that HNF4a is predicted to be inhibited in PRMT1 KO mice and b-catenin is predicted to be activated (Supporting Fig. S3B ).
To confirm these results, we performed series of experiments to analyze those pathways apparently regulated by PRMT1. We found that b-catenin protein levels were increased 3-fold in PRMT1 KO livers (Fig.  2B,C) . However, we found no change in b-catenin mRNA levels (Fig. 2D ). These data suggest that bcatenin stability was increased. b-catenin is a part of the b-catenin/APC (adenomatous polyposis coli)/Axin complex, and binding by APC/Axin results in bcatenin phosphorylation and degradation. Lack of complex components or increased glycogen synthase kinase-3 beta kinase activity can result in b-catenin accumulation. (26) We analyzed the expression of those genes and found that only Axin1 mRNA was decreased in PRMT1 KO compared to WT livers (Fig. 2D) . Previous studies showed that PRMT1 regulates b-catenin signaling through expression of Axin1. (27) Our data suggest that, in hepatocytes, PRMT1 also regulates Axin1 gene expression. Interestingly we found that only a subset of downstream bcatenin target genes were up-regulated in PRMT1 KO mouse liver, whereas others were not changed or inhibited (Fig. 2E) . These data suggest that activation of the b-catenin pathway may not be responsible for the increase in hepatocyte proliferation.
Next, we analyzed the direct effect of PRMT1 deletion on HNF4a. Previously, it has been shown that PRMT1 can bind and methylate HNF4a, as well as its target gene promoters, and regulate HNF4a activity. (3) We found that HNF4a mRNA expression itself is also regulated by PRMT1 (Fig. 2F) , possibly because HNF4a is its own target gene. We also analyzed the expression of HNF4a target genes (28) and confirmed that genes that are suppressed by HNF4a are upregulated in PRMT1 KO and genes that are induced by HNF4a are inhibited by PRMT1 KO (Fig. 2F) . These data suggest that PRMT1 regulates expression of both HNF4a and its downstream target genes.
PRMT1 REGULATES HNF4a AND Axin1 GENE EXPRESSION THROUGH PROMOTER HISTONE ARGININE METHYLATION
Next, we examined the mechanism of PRMT1 regulation of HNF4a and Axin1 gene expression. Previously, we showed that PRMT1 regulates expression through H4R3me2a histone methylation of gene promoters. (2, 4) H4R3me2a promotes recruitment of acetyltransferases and transcriptional activation of the target genes. (6) PRMT1 KO livers have dramatically lower global levels of H4R3me2a compared to WT litter mates (Fig. 3A) . We analyzed histone arginine methylation of APC, Axin1, Axin2, and HNF4a and found that PRMT1 KO livers have significantly lower levels of methylation at Axin1 and HNF4A promoters (Fig. 3B,C) . Furthermore, binding of HNF4a to its target promoters, including its own promoter, is reduced in KO livers (Fig. 3D) .
Previous studies indicated that HNF4a inhibition or b-catenin activation results in an increase of c-Myc expression, which promotes proliferation. (15, 26, 28) However, we did not observe an increase in c-Myc mRNA in the PRMT1 KO ( Fig. 2A) . These data suggest that the increase in proliferation observed in PRMT1 KO mice is c-Myc independent. It also raises the question of why HNF4a inhibition in the context of loss of PRMT1 fails to activate c-Myc expression. This lack of c-Myc activation is likely explained by the direct regulation of c-Myc promoter activity by PRMT1-dependent promoter methylation.
(2) c-Myc promoter methylation is dramatically decreased by the PRMT1 KO (Fig. 3E) .
Finally, we confirmed that PRMT1 regulates gene expression of Axin1 and HNF4a in vitro using Huh 7.5 cells expressing WT PRMT1 (Fig. 3F) . We found that PRMT1 overexpression can induce expression of those genes and it requires PRMT1 activity, because treatment with the PRMT1 inhibitor AMI-1 prevents this induction.
PRMT1-DEPENDENT HISTONE METHYLATION IS INHIBITED IN ALCOHOL-FED MICE
To confirm that loss of PRMT1 activity is relevant in human disease, we analyzed H4R3me2a levels in the livers of donors or patients with nonalcohol steatohepatitis (NASH), alcoholic liver disease (ALD), and primary biliary cirrhosis (PBC; Fig. 4A ). H4R3me2a levels vary between individuals, but only the ALD group showed significantly lower levels compared to normal liver donors. To confirm the presence of this mechanism using a mouse model of alcohol feeding, we measured H4R3me2a levels in livers of mice fed alcohol or control liquid diet for 10 days or 3 weeks (Fig. 4B) . We did not observe any change in the total level of H4R3me2a in these animals. Interestingly, PRMT1 protein level increased at 10 days of alcohol feeding compared to control animals. These data suggest that inhibition of PRMT1 activity is not profound enough and/or the duration of inhibition is not long enough to suppress total histone methylation. We thus hypothesized that alcohol might affect methylation more selectively at specific promoters. We found that at 3 weeks, but not 10 days, of alcohol feeding, specific histone arginine methylation at the promoters of Axin1, Axin2, and HNF4a was reduced (Fig. 4C,D) . Additionally, we found that ethanol feeding produced small, but significant, decreases in Axin1, APC, and HNF4a mRNA and increases in a subset of b-catenin target gene expression. The decrease in HNF4a mRNA was associated with the predicted changes in its target genes, apolipoprotein B (Apob) and epithelial cell transforming sequence 2 (Ect2; Fig. 4E ). These effects of alcohol were similar to those observed in PRMT1 KO animals in comparison to WT litter mates (Fig.  2D-F) . We found no significant change in b-catenin, c-Myc, and JMJD6 protein levels at these conditions (Supporting Fig. S4 ).
AAV-Cre MEDIATED PRMT1 DELETION IN ADULT MICE RESULTS IN INHIBITION OF HNF4a EXPRESSION AND AN INCREASE IN HEPATOCYTE PROLIFERATION
Given that Albumin Cre-genetic deletion of genes in hepatocytes can have off-target effects, such as Cre expression in biliary cells or expression during development, we confirmed our observations using a second model of PRMT1 deletion in hepatocytes, AAV8-TBG-Cre or AAV-control virus injection into adult PRMT1 fl/fl mice (Fig. 5) . Figure 5A shows that this treatment eliminated detectible ADMA staining in nearly 100% of hepatocytes. At 3 weeks post-AAV injection, we observed a dramatic increase in PCNApositive cells in liver (Fig. 5A ) and an increase in liver/ body weight ratio from 5.2% to 6.2% (Fig. 5B) . We also detected an increase in proliferation-related genes in KO animals (Fig. 5C) . Interestingly, PRMT1 KO reduced the expression of Axin1 (Fig. 5D ), but bcatenin level was not increased and its downstream target gene expression was not activated and was even decreased (Fig. 5D,E) . These data suggest that PRMT1 might have other targets in the b-catenin pathway apart from Axin1. (27, 29) Previous studies found that PRMT1 can positively regulate the bcatenin pathway through arginine methylation of GTPase-activating SH3 domain-binding protein 1 (G3BP1). (30) Next, we examined HNF4a expression and found that PRMT1 knockout in adults resulted in a decrease in protein and mRNA levels of HNF4a, decrease in promoter arginine methylation, as well as loss of HNF4a-mediated activation of Apob or suppression of Ect2 and Cyclin D (Fig. 5F and Supporting Fig.  S5A,B) . These data are consistent with reports suggesting that reduced expression of Hnf4a is sufficient to induce an increase in hepatocyte proliferation. (28) Taken together, these data suggest that PRMT1 regulates hepatocyte proliferation mainly through HNF4a regulation.
To determine whether differences between the albumin-cre and the AAV-Cre models is simply attributed to time of exposure to PRMT1 KO, we injected AAV-Cre to induce PRMT1 KO for 12 weeks (Fig. 5F and Supporting Fig. S5B ). We found a decrease in protein and mRNA levels of HNF4a as well as accumulation of b-catenin protein, similar to the situation in the Alb-Cre mice, but without the increase in expression of the downstream gene, WNT1-inducible signaling pathway protein 1, observed in the Alb-Cre KO (Supporting Fig. S5B vs.  Fig. 2 ).
JMJD6 KNOCKDOWN CAN RESTORE ADMA AND HNF4a LEVELS IN PRMT1 KO MICE
Until recently, arginine methylation was thought to be a stable modification, which can be removed only through degradation and synthesis of new unmethylated proteins. However, recent studies from our lab and others have found that JMJD6 can demethylate some of the PRMT1 targets. (8, 9, 11) Apart from being a demethylase, JMJD6 also has other functions that make it hard to evaluate its role in vitro and in vivo. Here, we decided to study whether JMJD6 has the opposing role in regulating PRMT1 targets that are important for hepatocyte proliferation (Fig. 6) . First, we analyzed how JMJD6 overexpression affects FIG. 6 HNF4a and Axin1 expression in vitro in Huh 7.5 cells (Fig. 6A) . We found that JMJD6 suppresses expression of both genes in vitro, suggesting that it can have an opposite effect to that of PRMT1.
Next we analyzed the role of JMJD6 in vivo. PRMT1 fl/fl mice received injection of AAV8-TBGcre or control AAV (adeno-associated virus). Three days later, mice received a second injection of AAV8-JMJD6 shRNA (short hairpin RNA) or AAV8 scrambled control. Three weeks postinjection, mice were analyzed. We found that in the JMJD6 shRNA group PRMT1 KO did not result in a significant increase in liver weight compared to WT control (Fig. 6B) . We confirmed that this was not attributed to inefficient recombination, given that both KO groups had a similar level of PRMT1expression (Fig. 6B and Supporting S6A,B). JMJD6 knockdown partially restored ADMA levels in PRMT1 KO mice (Fig. 6C) . JMJD6 knockdown also reduced Cyclin B and Cyclin D expression and increased HNF4a expression in livers of PRMT1 KO mice (Fig. 6D,E) . Similarly, we observed a decrease in the number of PCNA-positive cells in livers of PRMT1 KO mice that received JMJD6 shRNA compared to mice that received scrambled shRNA (Fig. 6F) . Taken together, these data suggest that JMJD6 knockdown can restore HNF4a levels in PRMT1 KO hepatocytes and prevent an increase in hepatocyte proliferation. Interestingly, JMJD6 knockdown did not restore ALT levels in those mice suggesting that gpt expression is not regulated by JMJD6 (Supporting Fig. S6C ).
JMJD6 KNOCKDOWN CAN RESTORE ADMA AND HNF4a LEVELS IN ALCOHOL-FED MICE
Next, we examined whether JMJD6 knockdown can restore arginine methylation in alcohol-fed mice. WT mice were fed alcohol or control liquid diet for 3 weeks, and on the first day of alcohol, mice received either AAV-JMJD6 shRNA or AAV-scrambled ( Fig. 7 and Supporting Fig. S7 ). We found that JMJD6 knockdown can increase ADMA levels in livers of alcohol-fed mice (Fig. 7A,B) . In addition, JMJD6 knockdown prevented HNF4a promoter demethylation induced by alcohol and efficiently restored HNF4a expression (Fig. 7C,D and Supporting Fig. S6A ). These data suggest that the reciprocal activities of PRMT1 and JMJD6 on ADMA regulate HNF4a expression in alcohol-fed mice. This is consistent with data presented in Figs. 5 and 6 . However, we found no effect of JMJD6 knockdown on expression of proliferation associated genes (Fig. 7D) , hepatocyte proliferation markers (Fig. 7E) , or liver size (Supporting Fig. S7B ), suggesting that alcohol increases hepatocyte proliferation independent of HNF4a inhibition.
ADMA LEVELS CORRELATE WITH HNF4a EXPRESSION IN HUMAN HCC
To confirm that PRMT1-and JMJD6-dependent ADMA regulation of HNF4a expression is relevant to human disease, we measured ADMA levels in the nucleus and HNF4a expression in HCC sections from liver explants of HCC patients undergoing liver transplantation. We found a significant correlation between those two parameters (Fig. 8A,B) . We also measured b-catenin expression in those tissues and found no correlation with ADMA (Fig. 8A) .
We found that in HCC samples, ADMA levels were significantly lower compared to livers with liver cirrhosis. However, there was no difference in ADMA levels between different etiologies of HCC (Fig. 8C) . Interestingly, PRMT1 protein levels were not decreased in HCC (Supporting Fig. S8 ) and were significantly higher than in donor livers. These data suggest that PRMT1 activity is altered in HCC, similar to the situation in alcohol-fed mice (Fig. 1A) .
We found that low ADMA also correlates with higher proliferation in human HCC (Fig. 8D) . We did not find any correlation with tumor size, possibly 11 gc/mouse followed by second injection of AAV8-GFP-U6-m-JMJD6-shRNA or AAV8-GFP-U6-scrmb-shRNA 2 3 10 11 gc/mouse. *P < 0.05; ***P < 0.001; n 5 4-6 per group. Relative mRNA levels of PRMT1 and JMJD6 in livers of these mice is presented below. Data are presented as mean 6 SD; **P < 0.01. 1122 because most of the HCCs were treated with chemoembolization therapy one or multiple times before transplant. However, the number of tumors at time of transplant was significantly higher in the group with low ADMA compared to the high-ADMA group (Fig. 8E ).
Discussion
HCC is the third-most common cause of cancerrelated death. (31, 32) Unlike other cancers with known risk factors, causes of HCC are not completely understood. Most HCC patients have a history of chronic liver disease and cirrhosis. (12) Commonly, the HCC is associated with hepatitis B and C or chronic alcohol drinking. (13) HCC development is a multistep process that involves genetic and epigenetic modifications in the liver that lead to malignant transformation of hepatocytes. (33) Alcohol promotes liver tumors by multiple mechanisms. (15) (16) (17) (18) Here, we describe a mechanism of alcohol pathogenesis that can contribute to tumor development. We found that alcohol can dramatically reduce cellular arginine methylation levels. By studying the impact loss of arginine methylation can have on cellular processes, we found that two enzymes-the methyltransferase, PRMT1, and the demethylase, JMJD6-can positively (PRMT1) and negatively (JMJD6) regulate levels of cellular asymmetric dimethyl arginine and histone arginine methylation at promoters of target genes. Specifically they regulate expression of HNF4a in hepatocytes. Loss of PRMT1 results in dramatic down-regulation of HNF4a in the liver and an increase in hepatocyte proliferation. JMJD6 knockdown, on the other hand, can restore HNF4a levels in PRMT1 KO hepatocytes and prevent the increase in proliferation.
Interestingly, we found that genetic ablation of PRMT1 in hepatocytes resulted in up-regulation of bcatenin; however, we found no increase in downstream target gene expression. Similar results were found in the conditional KO model (AAV-Cre) after 12 weeks post-AAV injections. Studies have also described a dependence of steady-state b-catenin level on PRMT1 with PRMT1 knockdown causing an increase through effects of Axin1 and G3BP1. (27, 30) Although our data confirm that PRMT1 knockdown increases b-catenin level, we fail to see a subsequent increase in downstream target expression. This suggests that PRMT1 KO has a second effect that prevents increased expression of these targets.
Alcohol feeding duplicates some, but not all, of the PRMT1 KO effects. Similar to PRMT1 KO, alcohol caused reduced promoter arginine methylation and gene expression of HNF4a and Axin1. Downstream HNF4a signaling was similarly inhibited in both alcohol and PRMT1 KO models. Alcohol feeding resulted in up-regulation of a subset of b-catenin target genes, which was not present in the PRMT1 conditional KO model. PRMT1 KO resulted in dramatic increase in hepatocyte proliferation. Alcohol feeding also resulted in higher hepatocyte proliferation, but the increase in proliferation was not attributed to reduced ADMA levels, because restoring ADMA with JMJD6 knockdown did not prevent it.
On the other hand, restoring ADMA levels by JMJD6 knockdown was sufficient to induce HNF4a expression in alcohol-fed mice to the control levels. Additionally, we found that there is a strong correlation between ADMA and HNF4a as well as proliferation in human HCC tissue specimen, suggesting that this mechanism is relevant in patients.
PRMT1 and JMJD6 in this setting play opposing roles in control of gene expression and proliferation. However, it is likely that not every target of PRMT1 is a target of JMJD6 as well. This study does not investigate the role of other methyltransferases, such as histone-arginine methyltransferase 1 and PRMT5, which are known to have different substrate specificity, whether or not those enzymes are affected by alcohol and whether or not JMJD6 can demethylate their targets. This important aspect will require further investigation.
We found that PRMT1 and JMJD6 regulate HNF4a. HNF4a is an important regulator of hepatic function. Apart from its role in controlling hepatocyte differentiation, recent studies identified it as a regulator of hepatocyte proliferation. (28, 34) HNF4a is downregulated in the majority of HCC. (35) (36) (37) Recent studies have demonstrated that inhibition or loss of HNF4a plays a key role in tumorigenesis in the liver and colon. (35, 38) PRMT1 also regulates other transcription factors that are involved in regulation of cell-cycle progression and proliferation, such as FOXOs, (22) p53, (6) cMyc, (2, 39) as well as upstream signaling molecules involved in proliferation, epidermal growth factor receptor. (40) We analyzed PRMT1 KO mouse gene expression and used IPA analysis to find the main upstream regulators affected by PRMT1. For the top upstream regulators, we confirmed whether documented target genes were activated or inhibited by PRMT1 as predicted. Only the HNF4a target gene expression pattern correlated with its inactivation and increased hepatocyte proliferation phenotype. Taken together, the presented data suggest that the alcohol effect on hepatocyte ADMA levels can result in the suppression of HNF4a expression and contribute to alcohol-associated cancer development. We found that JMJD6 knockdown is an efficient way to restore HNF4a levels in alcohol-fed mice. Further studies are necessary to evaluate the efficiency of targeting JMJD6 in alcohol-induced cancer models. Studies indicate that JMJD6 is up-regulated in several types of cancers, and some studies suggest that it promotes cancer cell proliferation. (41) Future development of specific JMJD6 inhibitors might be a promising strategy in cancer therapy for HCC and other types of cancer.
